Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 10/20 | 0.34 |
| ▸ | FNTB | P49356 | 10/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23850585 | 0.96 | GHSR (0.38) | CXCR3GHSRFNTAFNTBDRD2 | |
| SCHEMBL24210470 | 0.95 | FNTA (0.34) | CXCR3GHSRFNTAFNTBCNR1 | |
| SCHEMBL23853414 | 0.91 | HTR2C (0.35) | CXCR3GHSRFNTAFNTBCNR1 | |
| SCHEMBL23850025 | 0.87 | GHSR (0.35) | CXCR3GHSRFNTAFNTBCCR2 | |
| SCHEMBL23853717 | 0.82 | CXCR3 (0.33) | CXCR3GHSRFNTAFNTBDRD2 | |
| SCHEMBL23853659 | 0.79 | GHSR (0.34) | CXCR3GHSRFNTAFNTB | |
| SCHEMBL10207359 | 0.79 | NOTUM (0.38) | DRD2DRD4 | |
| SCHEMBL24210486 | 0.78 | FNTA (0.32) | FNTAFNTB | |
| SCHEMBL23853893 | 0.75 | BCHE (0.38) | — | |
| SCHEMBL10207446 | 0.74 | KDM4E (0.41) | DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017541-A1 | INHIBITORS OF ARGINASE | Praxis Biotech LLC | 2022-01-20 | — | — | US | disclosed |
| EP-3883938-A1 | INHIBITORS OF ARGINASE | Praxis Biotech LLC (US) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017541-A1 | INHIBITORS OF ARGINASE | ARG1, ARG2, ARGLU1 | CXCR3 2814/4885GHSR 2539/4885FNTA 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.